Halozyme Therapeutics | HALO - Ordinary Share Capital


Halozyme Therapeutics reported $118.52M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amarin USD 20.81M 13K Dec/2025
Amgen USD 540M 1000K Mar/2026
Baxter International USD 516.45M 2.17M Mar/2026
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
DBV Technologies USD 136.82M 51.98K Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
MannKind USD 308.91M 1.07M Mar/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
United Therapeutics USD 42.16M 1.49M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024